Scilex announced that it has entered into an agreement with a leading pharmacy chain in the U.S. to stock ELYXYB in over 500 stores which do not currently stock ELYXYB. Scilex is also in the process of negotiating similar potential stocking arrangements with other major pharmacy chains in the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SCLX:
- Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.
- Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024
- Scilex announces completion of commercial manufacturing of Gloperba
- Scilex shares reflect balance sheet risks, says B. Riley
- Scilex announces market research results on unmet needs treating acute migraine